Assessment of male sexual function

Lukacs, B.

doi:10.1038/sj.pcan.4500540

Cited by 14 publications

(12 citation statements)

References 9 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,3, In our study, no significant differences were detected in income levels. However, our study showed significantly higher prevalence of sexual dysfunction in the presence of chronic disease, smoking, younger and older age, lower educational level, and unmarried status in older age.…”

Section: Prevalence Of Msd and Potential Risk Factors In Turkish Men mentioning

confidence: 44%

“…1,2 Male sexuality is a complex entity involving several aspects, including desire, libido, pleasure, sexual life, intercourse, erection, ejaculation, orgasm, happiness, and bother. 3 Sexual dysfunction can be caused by various biological and psychological factors. The role of psychological factors in the onset and maintenance of sexual dysfunctions has been highlighted extensively in the literature.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence of male sexual dysfunction and potential risk factors in Turkish men: a Web-based survey

Öksüz

Malhan

2005

Int J Impot Res

View full text Add to dashboard Cite

The purpose of this study is to detect the prevalence of sexual dysfunction and also to investigate possible risk factors that may cause sexual dysfunction in Turkish men. We developed a Web-based survey. In total, 3185 invitations to complete the survey were e-mailed and 2288 individuals submitted responses (72%). The men were interviewed in person, using the Florida Sexual History Questionnaire (FSHQ) Turkish version, and sexual dysfunction was assessed by this questionnaire. male sexual dysfunction (MSD) was evaluated with FSHQ. According to the FSHQ Turkish version, sexual function domains included sexual desire, sexual development, intercourse, erection, ejaculation, and satisfaction. According to the FSHQ score, 43.3% reported on MSD (FSHQ scorep95). The prevalence of MSD was 56% in the ages of 15-24 y, 35% in 25-34 y, 26% in 35-44 y, 40% in the ages of 45-54 y, and 72% in the ages of 55-60 y. MSD was detected as a desire problem in 7.3%, sexual development problem in 54.7%, intercourse problem in 50.3%, arousal/erectile problem in 59.7%, orgasm/ejaculation problem in 52.7%, and satisfaction problem in 59.7%. The age-adjusted risk of developing MSD was higher for men with smoking, lower education, and chronic medical diseases. In conclusion, the prevalence of MSD is 43.3% in Turkish men. The most important risk factor for MSD is smoking. In addition, the presence of younger and older age, chronic medical diseases, and lower educational level are important risk factors that may cause MSD.

show abstract

Section: Prevalence Of Msd and Potential Risk Factors In Turkish Men mentioning

confidence: 44%

Section: Introductionmentioning

confidence: 99%

The prevalence of male sexual dysfunction and potential risk factors in Turkish men: a Web-based survey

Öksüz

Malhan

2005

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…Severity was measured using the International Index of Erectile Function (IIEF) questionnaire. According to the results, we divided the patients into three groups: Mild ED for scores of 22-25, mild-moderate for scores of 11-21, and severe for scores of 6-10 [8]. …”

Section: Methodsmentioning

confidence: 99%

Cardiovascular Risk Assessment Using High-Sensitivity C-Reactive Protein in Patients with Erectile Dysfunction

et al. 2013

View full text Add to dashboard Cite

Background: Erectile dysfunction (ED) is associated with cardiovascular events. High-sensitivity C-reactive protein (hsCRP) is a cardiovascular risk marker. The aim of this study is to determine whether hsCRP is useful in evaluating ED. Methods: In 121 patients with ED, age, ED type and severity, time since onset of ED, weight, height, BMI, body fat percentage, waist and hip circumference, hsCRP and hormone profile were studied. Patients were classified as low or moderate-high cardiovascular risk based on hsCRP levels. A descriptive and univariate study was performed. A logistic regression was used to establish factors associated with low versus moderate-high cardiovascular risk and hsCRP. Results: Most patients had moderate-severe ED (70%). 74% had a moderate-high cardiovascular risk based on hsCRP levels, and 33.9 and 34.7% had hypogonadism according to total (TT) and free testosterone. In the univariate analysis, a relationship between hsCRP and TT and physical examination variables was observed (p < 0.05). In the multivariate analysis, TT was found to be a predictor (OR: 0.676; 95% CI: 0.491-0.029). Higher cardiovascular risk was found in the hypogonadic group (OR: 5.51; 95% CI: 1.185-25.662) and waist- to-hip ratio (p = 0.008; OR: 1.361; 95% CI: 1.075-1.612). Conclusions: A majority of patients with ED have high cardiovascular risk based on hsCRP levels and there is an association with hypogonadism and obesity.

show abstract

“…To assess male sexual functions, we decided to use the validated questionnaire ‘International Index of Erectile Function’ (IIEF), which is also available in national language, and which is, in our opinion, better and less biased than the QoSL‐Q (Rosen et al. , 1997, 1999, 2002; Lukacs, 2001).…”

Section: Introductionmentioning

confidence: 99%

Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6‐month follow‐up

Pohanka¹,

Kaňovský

Bareš

et al. 2004

Euro J of Neurology

View full text Add to dashboard Cite

One of the most disabling problems in males suffering from advanced Parkinson's disease (PD) is complex sexual dysfunction. The effect of dopamine replacement or dopaminergic stimulation on sexual dysfunction has been recently examined and described in patients treated by L-DOPA or apomorphine. Pergolide mesylate is another dopamine agonist with a known high affinity to hD(2S) subtype and a lower affinity to hD(2L) subtype of D2 dopaminergic receptors. It has been repeatedly shown to be a highly effective treatment of the complicated and advanced stages of PD. The current study has been designed to assess its efficacy in the treatment of sexual dysfunction, which frequently accompanies the complicated stage of PD in males. Fourteen male patients suffering from PD, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a 6-month period. Pergolide mesylate (Permax) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. The assessments performed before the start of pergolide treatment consisted of a neurological examination, including Unified Parkinson's Disease Rating Scale (UPDRS) III and IV subscales scoring, Mini Mental State Examination (MMSE) scoring, the neuropsychological examination including Zung scale scoring to exclude depression, biochemical and haematological examinations including the examination of prolactine serum levels; and a sexological examination during which the patients filled-in the International Index of Erectile Function (IIEF) questionnaire. These examinations were repeated during the control assessments at months 1, 3 and 6. To compare the examination results, anova, Friedmann's anova (non-parametric) and Tukey post hoc tests were used. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3 and 6. The differences between months 0 and 1 and months 3 and 6 (in these items) were virtually insignificant. In conclusion, pergolide substantially improved sexual function in the younger male patients who were still interested in sexual activities. In such cases, the introduction of pergolide might be a better choice than treatment with sildenafile, which usually meets several contraindications in common PD male population.

show abstract

Assessment of male sexual function

Cited by 14 publications

References 9 publications

The prevalence of male sexual dysfunction and potential risk factors in Turkish men: a Web-based survey

The prevalence of male sexual dysfunction and potential risk factors in Turkish men: a Web-based survey

Cardiovascular Risk Assessment Using High-Sensitivity C-Reactive Protein in Patients with Erectile Dysfunction

Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6‐month follow‐up

Contact Info

Product

Resources

About